Spiraeoside

Spiraeoside is a flavonoid glycoside composed of quercetin-4'-O-glucoside, found naturally in plants such as meadowsweet (Filipendula ulmaria) and onions. It exerts its primary effects through antioxidant and anti-inflammatory mechanisms, including suppression of reactive oxygen species and inhibition of pro-inflammatory signaling pathways.

Origin & History

Spiraeoside is a flavonoid glycoside, specifically quercetin 4'-O-beta-D-glucopyranoside, naturally occurring in the flowers of meadowsweet (Filipendula ulmaria) and garden onion (Allium cepa). It is isolated as a light yellow to yellow solid powder with ≥98% purity for research purposes.

Historical & Cultural Context

No historical or traditional medicinal uses are documented in available sources. Spiraeoside is primarily described as a modern research compound isolated from Filipendula ulmaria and Allium cepa.

Health Benefits

• Cardiovascular protection: Protects AC16 cardiomyocytes against high glucose-induced oxidative stress and apoptosis (in vitro evidence only)
• Antioxidant activity: Inhibits reactive oxygen species (ROS) and malondialdehyde production (preclinical evidence)
• Anti-inflammatory effects: Inhibits mast cell activation and IgE-mediated allergic responses (cell-based studies)
• Potential antitumor properties: Demonstrated antineoplastic activity (mechanism-based evidence only)
• Anti-plasmin activity: Shows inhibition of plasmin and DENV-NS5 RdRp (in vitro evidence)

How It Works

Spiraeoside functions as a quercetin-4'-O-glucoside that scavenges reactive oxygen species (ROS) and reduces malondialdehyde (MDA) production, thereby limiting lipid peroxidation at the cellular level. It modulates the Nrf2/HO-1 antioxidant pathway and suppresses NF-κB-driven transcription of pro-inflammatory cytokines such as TNF-α and IL-6. In cardiomyocyte models, it also inhibits mitochondria-dependent apoptotic signaling by regulating Bcl-2/Bax protein ratios and reducing caspase-3 activation under high-glucose oxidative conditions.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses on spiraeoside were identified. All available evidence is limited to preclinical studies, including in vitro protection of AC16 cardiomyocytes against oxidative stress and cell-based demonstrations of antioxidant and anti-inflammatory activities.

Clinical Summary

Current evidence for spiraeoside is derived exclusively from in vitro and preclinical animal studies; no published human clinical trials exist as of 2024. In vitro work using AC16 human cardiomyocyte cell lines demonstrated that spiraeoside reduces high glucose-induced ROS accumulation and apoptosis in a concentration-dependent manner. Preclinical models have also shown anti-inflammatory activity through cytokine suppression, though specific quantified effect sizes and effective concentrations vary across studies. The overall evidence base is early-stage, and translating these findings to human therapeutic applications requires rigorous clinical investigation.

Nutritional Profile

Spiraeoside (quercetin-4'-O-glucoside; C₂₁H₂₀O₁₂; MW 464.38 g/mol) is a flavonol glycoside, not a food or nutrient per se, so it lacks a conventional macronutrient/micronutrient profile. Key details: • Classification: Flavonoid glycoside — specifically a monoglucosylated conjugate of quercetin, with glucose attached at the 4'-hydroxyl position. • Natural sources and approximate concentrations: Found primarily in onion bulbs (Allium cepa), where it is one of the dominant quercetin glycosides alongside quercetin-3,4'-di-O-glucoside; concentrations in yellow/brown onions range from approximately 50–300 mg/kg fresh weight depending on cultivar and growing conditions. Also identified in flowers of Filipendula ulmaria (meadowsweet) and various other plant species. • Bioactive compound class: Flavonol glycoside with documented antioxidant (DPPH and ABTS radical scavenging, ROS inhibition), anti-inflammatory (mast cell stabilization, NF-κB pathway modulation), cardioprotective (protection against high-glucose-induced oxidative stress in cardiomyocytes), and potential antitumor activities. • Bioavailability notes: As a quercetin-4'-O-glucoside, spiraeoside is expected to be absorbed in the small intestine via sodium-dependent glucose transporter 1 (SGLT1) and/or after hydrolysis by lactase-phlorizin hydrolase (LPH) at the brush border membrane, liberating free quercetin — a pathway shared with quercetin-4'-glucoside isomers. Quercetin glucosides from onions demonstrate substantially higher bioavailability (estimated 3–5× greater absorption) compared to quercetin aglycone or quercetin-rutinoside (rutin). Peak plasma concentrations of total quercetin metabolites following onion consumption (providing ~70–100 mg quercetin equivalents) reach approximately 0.6–7.6 µM, with a Tmax of ~0.5–1 hour. Extensive phase II metabolism yields glucuronidated, sulfated, and methylated conjugates as the predominant circulating forms. • No macronutrients (protein, fat, carbohydrate, fiber), vitamins, or minerals are attributable to spiraeoside itself as an isolated compound. • Caloric contribution: Negligible at pharmacologically or dietarily relevant doses.

Preparation & Dosage

No clinically studied dosage ranges are available as human clinical data is absent. Products containing spiraeoside are currently designated for research use only, not for human consumption. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Vitamin C, Nrf2 activators, Other flavonoid glycosides, Natural antioxidants

Safety & Interactions

No formal human safety trials or toxicology profiles for isolated spiraeoside exist in the published literature, making comprehensive risk characterization impossible at this time. Because spiraeoside is structurally related to quercetin, potential interactions with cytochrome P450 enzymes (particularly CYP3A4 and CYP2C9) and P-glycoprotein drug transporters are theoretically plausible, which could affect metabolism of anticoagulants, statins, or immunosuppressants. Pregnant and breastfeeding individuals should avoid supplemental spiraeoside due to a complete absence of safety data in these populations. Individuals taking blood-thinning medications such as warfarin should exercise caution given the quercetin backbone's known mild antiplatelet properties.